Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Radiotherapy and Oncology

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.radonc.2014.01.021PMID 24836861
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating.

  2014cited by this paper
• DNA damage induced by nitric oxide during ionizing radiation is enhanced at replication.

  2013cited by this paper
• A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.

  2013cited by this paper
• Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas

  2013cited by this paper
• GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.

  2013cited by this paper
• Target volume for postoperative radiotherapy in non-small cell lung cancer: results from a prospective trial.

  2013cited by this paper
• [National consensus of diagnosis and treatment of non-small cell lung cancer].

  2013cited by this paper
• Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention

  2012cited by this paper
• Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Normalization of the vasculature for treatment of cancer and other diseases.

  2011cited by this paper
• Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.

  2010cited by this paper
• Nitric oxide, derived from inducible nitric oxide synthase, decreases hypoxia inducible factor‐1α in macrophages during aspirin‐induced mesenteric inflammation

  2010cited by this paper
• A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

  2009cited by this paper
• Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application

  2009cited by this paper
• Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).

  2008cited by this paper
• Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

  2007cited by this paper
• Hypoxia in cancer: significance and impact on clinical outcome

  2007cited by this paper
• Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma

  2006cited by this paper
• HIF-1 and tumour radiosensitivity

  2006cited by this paper
• Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

  2006cited by this paper
• Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.

  2006cited by this paper
• Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α

  2006cited by this paper
• Nitric Oxide and Ionizing Radiation Synergistically Promote Apoptosis and Growth Inhibition of Cancer by Activating p53

  2004cited by this paper
• Redistribution of Intracellular Oxygen in Hypoxia by Nitric Oxide: Effect on HIF1α

  2003cited by this paper
• Potentiation of radiation‐induced regrowth delay by isosorbide dinitrate in FSaII murine tumors

  2003cited by this paper
• Mechanisms of nitric oxide generation from nitroglycerin and endogenous sources during hypoxia in vivo

  2002cited by this paper
• Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

  2001cited by this paper
• Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI.

  2000cited by this paper
• Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation

  1999cited by this paper
• Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

  1999cited by this paper
• Oxidative damage of mitochondrial and nuclear DNA induced by ionizing radiation in human hepatoblastoma cells.

  1998cited by this paper
• Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

  1995cited by this paper
• Hypoxic mammalian cell radiosensitization by nitric oxide.

  1993cited by this paper

• Screening for ferroptosis genes related to endometrial carcinoma and predicting of targeted drugs based on bioinformatics

  2024cites this paper
• Repurposing radiosensitising medicines for radiotherapy: an overview

  2024cites this paper
• Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

  2023cites this paper
• Nitric Oxide Prevents Glioblastoma Stem Cells’ Expansion and Induces Temozolomide Sensitization

  2023cites this paper
• GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC

  2023cites this paper
• Nitroglycerin: a comprehensive review in cancer therapy

  2023cites this paper
• Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.

  2022cites this paper
• Nitric Oxide and Tumors: From Small-Molecule Donor to Combination Therapy.

  2022cites this paper
• The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions

  2022cites this paper
• Impact of nitric oxide in liver cancer microenvironment.

  2022cites this paper
• Nitroglycerin plus whole intracranial radiotherapy for brain metastases in non-small cell lung cancer patients: A randomized, open-label, phase II clinical trial.

  2022cites this paper
• Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics

  2021cites this paper
• Integrative Bioinformatics approaches to therapeutic gene target selection in various cancers for Nitroglycerin

  2021cites this paper
• The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases

  2021cites this paper
• Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells

  2021cites this paper
• Tumor hypoxia: the major culprit behind cisplatin resistance in cancer patients.

  2021cites this paper
• Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways

  2020cites this paper
• Strategies for engineering advanced nanomedicines for gas therapy of cancer

  2020cites this paper
• Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy

  2020cites this paper
• Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.

  2020cites this paper
• Senescence and Cancer: Role of Nitric Oxide (NO) in SASP

  2020cites this paper
• Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells

  2019cites this paper
• Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?

  2019cites this paper
• Controlled Delivery of Nitric Oxide for Cancer Therapy

  2019cites this paper
• Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial

  2019cites this paper
• S-Nitrosylation of cIAP1 Switches Cancer Cell Fate from TNFα/TNFR1-Mediated Cell Survival to Cell Death.

  2018cites this paper
• Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome

  2018cites this paper
• Targeting antioxidant enzymes as a radiosensitizing strategy.

  2018cites this paper
• The metal-nonoate Ni(SalPipNONO) inhibits in vitro tumor growth, invasiveness and angiogenesis

  2018cites this paper
• Longitudinal Evaluation of Lung Function in Patients With Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy.

  2018cites this paper
• Nitric Oxide and Platinum-Derivative-Based Regimens for Cancer Treatment: From Preclinical Studies to Clinical Trials

  2017cites this paper
• Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.

  2017cites this paper
• Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer.

  2016cites this paper
• [NO and cancer: itinerary of a double agent].

  2016cites this paper
• Itinéraire d’un agent double - NO, S-nitrosylation et cancer

  2016cites this paper
• Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs.

  2015cites this paper
• Emerging Role of NO-Mediated Therapeutics

  2015cites this paper
• Role of Nitric Oxide in the Regulation of the Pro-tumourigenic Hypoxic Phenotype: From Instigation to Mitigation

  2015cites this paper
• Nitric Oxide Attenuates Hypoxia-Induced 5-FU Resistance of Oral Squamous Cell Carcinoma Cells

  2015cites this paper
• Gasotransmitters in cancer: from pathophysiology to experimental therapy

  2015cites this paper
• Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics☆

  2015cites this paper
• Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

  2015cites this paper
• Cutting-edge research in basic and translational radiation biology/oncology reflections from the 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2015.

  2015cites this paper
• NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001☆

  2015cites this paper
• Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent

  2015cites this paper
• In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging

  2014cites this paper
• Personalized Medicine and Imaging In Vivo Quanti fi cation of Hypoxic and Metabolic Status of NSCLC Tumors Using [ 18 F ] HX 4 and [ 18 F ] FDG-PET / CT Imaging

  2014cites this paper